Wegovy Pill UK: Oral Semaglutide Release Date, Cost & What It Means for Weight Loss (2026/27)

What Is the Wegovy Pill?

The Wegovy pill — known clinically as oral semaglutide — is a once-daily tablet form of the same active ingredient found in the Wegovy injection. Semaglutide is a GLP-1 receptor agonist, a class of medicines that mimic the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and regulate blood sugar levels.

Until now, semaglutide for weight loss has only been available as a weekly subcutaneous injection (Wegovy). The oral version represents a significant shift — removing the need for needles entirely and potentially making GLP-1 treatment far more accessible to a wider population.

Is the Wegovy Pill Available in the UK?

No. As of June 2026, the oral Wegovy pill is not yet available in the UK. It is currently undergoing regulatory review by the Medicines and Healthcare products Regulatory Agency (MHRA).

A UK approval decision is expected in late 2026. If approved, private availability is anticipated shortly after — similar to how Wegovy and Mounjaro injections launched privately before NHS access followed. NHS availability will require an additional review by the National Institute for Health and Care Excellence (NICE), which typically adds a further 6 to 9 months to the timeline.

The oral semaglutide tablet was approved by the FDA in the United States in 2025 for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Key Points on UK Availability

• Regulatory Status: Pending MHRA licensing for weight loss in the UK. The once-daily oral tablet has already been approved in the US.
• Private vs NHS Access: Private clinics and pharmacies will likely offer it first. NHS availability depends on a subsequent NICE review, typically adding 6–9 months.
• Current Alternatives: Until the Wegovy pill is approved, the weekly Wegovy injection (semaglutide) remains the primary licensed weight management option, alongside Mounjaro (tirzepatide).

How Does the Wegovy Pill Compare to the Injection?

Both the pill and the injection contain semaglutide, but they work differently in the body. The injection delivers semaglutide directly into subcutaneous tissue, where it is absorbed slowly over the week. The tablet uses a special absorption enhancer (SNAC) to allow semaglutide to pass through the stomach lining — without it, the molecule would be broken down by stomach acid before reaching the bloodstream.

Clinical trials (the OASIS programme) showed the oral semaglutide tablet at 50mg daily produced meaningful weight loss — though slightly less than the 2.4mg weekly injection in head-to-head comparisons. However, for many patients, the convenience of a daily pill over a weekly injection will outweigh a modest difference in efficacy.

How Much Could the Wegovy Pill Cost in the UK?

Pricing has not yet been confirmed for the UK market. However, based on US pricing and the trajectory of injectable GLP-1 medicines in the UK, we can make some informed projections:

• In the US, oral semaglutide for weight loss is priced similarly to the injection — around $1,300–$1,400 per month without insurance.
• In the UK private market, Wegovy injections currently range from approximately £200–£350 per month depending on dose and pharmacy.
• The oral pill may launch at a similar or slightly lower price point — manufacturers have an incentive to price competitively to drive adoption, particularly given the larger addressable market a pill format opens up.

At MedEazy, we will compare oral semaglutide prices across verified UK pharmacies as soon as it becomes available — just as we do for Wegovy, Mounjaro, Saxenda, and Orlistat today.

What Does This Mean for Weight Loss Affordability in the UK?

This is where the oral GLP-1 story gets genuinely exciting. The injectable GLP-1 market has been constrained by two factors: needle aversion and supply shortages. A pill format addresses the first directly — and as manufacturing scales, it should help ease the second over time.

Greater accessibility means a larger patient pool, which in turn drives competition between pharmacies and manufacturers. More competition typically means lower prices. If the oral Wegovy pill launches at a competitive price point and supply is stable, it could meaningfully reduce the cost of GLP-1 treatment in the UK private market over the next 12–24 months.

For the millions of UK adults living with obesity who have avoided injectable treatments due to needle phobia, the pill format could be transformative — not just clinically, but economically. A more accessible treatment option with broader uptake creates the conditions for a more competitive, affordable market.

Can I Register My Interest Now?

Yes. Several major UK telehealth platforms — including ZAVA UK and Superdrug Online Doctor — are already accepting waitlist registrations for oral semaglutide. Registering early puts you in the queue for when MHRA approval comes through and private supply begins.

MedEazy will list and compare oral semaglutide prices from verified, GPhC-registered UK pharmacies as soon as they are available. Compare current Wegovy injection prices here while you wait.

Summary

• The Wegovy pill (oral semaglutide) is approved in the US but not yet available in the UK
• MHRA approval is expected in late 2026, with private availability to follow
• NHS access will require a further NICE review — likely 2027 at the earliest
• Pricing is unconfirmed but expected to be broadly in line with the injection
• The pill format could significantly expand access and drive down GLP-1 costs in the UK over time
• MedEazy will compare prices as soon as it launches — see current Wegovy prices here